pharmaceuticals

Some U.S. Congresspeople want to limit direct to consumer marketing of drugs. Rep. Bart Stupak is head of the U.S. House of Representatives Energy and Commerce investigative panel. At a hearing to discuss specific ads by Pfizer, Johnson & Johnson, Merck and Schering-Plough, Stupak said that "It appears that we need to enforce significant restrictions on DTC (direct–to–consumer) ads to protect American consumers from manipulative commercials designed to mislead and deceive for the profit of pharmaceutical companies." Referring to the fact that other than New Zealand, the U.S. is the only country to allow direct to consumer advertising of drugs he added, "Pharmaceutical companies should consider it a privilege to be allowed to air DTC ads in this country. We should make sure that pharmaceuticals companies conduct themselves responsibly." The ranking Republican on the committee, John Shimkus of Illinois, said that since the Food and Drug Administration was just recently given oversight of drug ads, it is too soon for congressional intervention. But as CMD has reported previously, there is significant concern as to whether the FDA and other government agencies are able and willing to stand up to industry and government pressure.

Listen to this week's edition of the "Weekly Radio Spin," the Center for Media and Democracy's audio report on the stories behind the news. This week, we look at radio shows on drugs, when U.S. think tanks meddle overseas, and mad policies on mad cow. In "Six Degrees of Spin and Fakin'," we look at Dow's chemical legacy. The Weekly Radio Spin is freely available for personal and broadcast use. Podcasters can subscribe to the XML feed on www.prwatch.org/audio or via iTunes. If you air the Weekly Radio Spin on your radio station, please email us at editor@prwatch.org to let us know. Thanks!

"Prozac Nation: Revisited," a show that aired on U.S. National Public Radio member stations, "featured four prestigious medical experts discussing the controversial link between antidepressants and suicide. ... All four said that worries ... have been overblown." But the show did not disclose that all four "have financial ties to the makers of antidepressants," or that the series that produced the show, "The Infinite Mind," has received "unrestricted grants" from drug companies including Eli Lilly, the maker of Prozac. One guest, Peter Pitts, heads the industry-funded Center for Medicine in the Public Interest and is "senior vice president for global health affairs at the PR firm Manning Selvage & Lee," which counts among its clients Eli Lilly, GlaxoSmithKline, Pfizer and "more than a dozen other pharmaceutical companies." In other drug news, Congressman Bart Stupak held a hearing titled "Direct to Consumer Advertising: Marketing, Education or Deception?" Stupak said "he wants to lay the groundwork for future legislation to tighten controls on drug marketing," reports the Wall Street Journal. The hearing addressed such "recent controversies" as ads for Pfizer's Lipitor, where artificial heart inventor Robert Jarvik "appears to be giving medical advice," and ads for Johnson & Johnson's anemia treatment Procrit that promote off-label uses for the drug.

At an inquiry into the problems facing cash-strapped public hospitals in New South Wales, Australia, neurologist Dr Suzanne Hodgkinson explained that doctors sought financial support of drug companies. "I had insufficient clerical support and so as to try and remedy that I approached a company to help me with that on a temporary, part-time basis. ... Quite a few senior doctors do try to raise money to help with the provision of services," she said. Hodgkinson raised A$20,000 for the position, but would not name the drug company funder. The president of the New South Wales branch of the Australian Medical Association, Dr Andrew Keegan, said the practice was common, especially for administrative roles. "I would assume it is happening in every major hospital, especially the teaching hospitals," he said. Opposition health spokeswoman Jillian Skinner said that "if it’s happening in our hospitals, there are ethical questions that need to be answered."

Listen to this week's edition of the "Weekly Radio Spin," the Center for Media and Democracy's audio report on the stories behind the news. This week, we look at how Barbie celebrates Earth Day, why Freedom's Watch is under scrutiny, and how some environmental groups could think giving "clean coal" a closer look makes sense. In "Six Degrees of Spin and Fakin'," we run down Merck's long history of using spin to counter their Vioxx scandal. The Weekly Radio Spin is freely available for personal and broadcast use. Podcasters can subscribe to the XML feed on www.prwatch.org/audio or via iTunes. If you air the Weekly Radio Spin on your radio station, please email us at editor@prwatch.org to let us know. Thanks!

Two studies of internal Merck documents concluded that the pharmaceutical company had "violated scientific-publishing ethics by ghostwriting dozens of academic articles, and minimized the impact of patient deaths in its analyses of some human trials." The internal documents surfaced during litigation against Merck, by people who had taken the painkiller Vioxx and suffered heart attacks or other problems. Five of the six authors of the studies, which were published by the Journal of the American Medical Association, "served as paid consultants to plaintiffs' lawyers in Vioxx lawsuits." One study found that medical papers on Vioxx "were often prepared by unacknowledged authors and subsequently attributed authorship to academically affiliated investigators who often did not disclose financial support." The other study concluded that Merck "neither provided to the FDA nor made public in a timely fashion" evidence that Vioxx use was linked to increased risk of death. A Merck researcher called the findings "false and misleading."

A rock cocaine cigarette filter? A cigarette that delivers birth control and sexual stimulant drugs to the smoker at the same time? A geriatric brand? All of these are actual ideas for new products and promotions that were recorded at cigarette company "brainstorming" meetings. Information about these revealing meetings is compiled on the Brainstorming documents page of TobaccoWiki. It's one of the strangest and most fun pages on SourceWatch. What crazy, weird or sick ideas can you find among the tobacco industry's documents? Go to the Legacy Tobacco Documents Library and, as search criteria, mix and match words like "brainstorming," "synectics," "exploratory" or "problem lab" with words like "promotional" "smoker," "ideas," "sex," "cigarette," "list," and "creative." Be imaginative in your search criteria and see what pops up. When you find something interesting, enter it on the Brainstorming documents page with a short description of the document after the link, or write a short article about it. Don't forget to link to the document using its unique URL -- the one that contains the letters "tid". For examples see the Brainstorming documents page. If this is your first time editing on SourceWatch, you can register here, and learn more about adding information to the site here, here and here. Hold onto your hat, have fun, and thanks for your help!

"I've never been on the opposite side of the NAACP," said Dr. Alicia Fernandez, an associate professor of clinical medicine. "I've been a big admirer of the SEIU" labor union. "But now these drug companies are going to the good guys for cover." In particular, the SEIU affiliate International Association of EMTs and Paramedics (IAEP) recently sent two letters to its members promoting Pfizer's cholesterol drug Lipitor. "IAEP leadership stands behind LIPITOR as the lipid-lowering agent of choice," read one letter, which was signed by IAEP director Matthew Levy and printed on IAEP letterhead, but with a Pfizer copyright at the end. IAEP stated it "does not endorse specific drugs," but refused to say whether the union has any financial relationship with Pfizer. In a similar case, the NAACP's New England branch accused Medicare of racism for refusing to cover the heart medication BiDil. (NitroMed, BiDil's manufacturer, has donated $1.5 million to the NAACP.) BiDil is a combination of two generic drugs that won "patent protection for treating African-American patients with heart failure." Fernandez believes NitroMed's "real goal" is "selling an expensive 'new' pill made from two cheap old ones." Meanwhile, she warned, "the argument over coverage of BiDil deflects attention from the real issues involved in health disparities."

Medicines Australia (MA), the peak drug industry lobby group, has unveiled details of how much its 42 member companies (and one non-member) spent in the last half of 2007 on each one of over 14,000 events that were designed to promote their drugs to doctors. In a backgrounder, MA claimed that under its self-regulatory code of conduct "the provision of lavish hospitality is banned." (The actual provision sets no thresholds for what constitutes "lavish" hospitality.) However, buried in the hundreds of pages of the reports are unprecedented details of expensive drug industry events. Roche spent $A511,791 on a three-day hepatitis symposium attended by 337 specialists at Melbourne's Grand Hyatt hotel. AstraZeneca forked out over $A514,000 for a weekend seminar at Crown Casino in Melbourne that was attended by 220 gastroenterologists and Pfizer spent $A340,000 on a cardiovascular forum for 220 specialists.

Listen to this week's edition of the "Weekly Radio Spin," the Center for Media and Democracy's audio report on the stories behind the news. This week, we look at BP's dirty oil, a front group against teen drinking and what state might ban drug industry goodies for doctors. In "Six Degrees of Spin and Fakin'," we name a few people who have stepped through the revolving door. The Weekly Radio Spin is freely available for personal and broadcast use. Podcasters can subscribe to the XML feed on www.prwatch.org/audio or via iTunes. If you air the Weekly Radio Spin on your radio station, please email us at editor@prwatch.org to let us know. Thanks!